Drug Trial Radar · NCT03375203
A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder
Last checked: Nov 20, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
365
Actual
Start
Nov 23, 2017
Primary completion
Apr 3, 2019
Study completion Apr 3, 2019
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Dec 15, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this 2 month phase 2b study is to investigate the dose response of 3 doses of JNJ-42847922 (Seltorexant) (5,10 and 20 mg) compared to placebo and zolpidem on sleep onset and maintenance and to further document safety and tolerability of JNJ-42847922 (Seltorexant) upon multiple (14 days) dose administration in participants with insomnia disorder.
Conditions
- Insomnia Disorders
Interventions
PlaceboDrug
Matching placebo will be administered once daily based upon dosing group.
JNJ-42847922, 5 mgDrug
JNJ-42847922 will be administered as 5 mg (2\*2.5 mg capsule) oral capsules once daily.
JNJ-42847922, 10 mgDrug
JNJ-42847922 will be administered as 10 mg oral capsule once daily.
JNJ-42847922, 20 mgDrug
JNJ-42847922 will be administered as 20 mg oral capsule once daily.
ZolpidemDrug
Zolpidem will be administered as 5 mg or 10 mg (2\*5mg capsule) oral capsule once daily based upon the local labeling information.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Latency to Persistent Sleep (LPS) as Measured by Polysomnography (PSG) on Night 1Time frame: Baseline and Night 1
Locations
56 sites in 6 countries. Site status is shown where the registry gives one.
Preferred Research Partners
Little Rock, Arkansas
Woodland Research Northwest
Rogers, Arkansas
California Research Trials DBA Orange Country Research Institute
Anaheim, California
Excell Research Inc
Oceanside, California
Artemis Institute for Clinical Research
San Diego, California
Empire Clinical Research, LLC
Upland, California
St. Francis Medical Institute
Clearwater, Florida
Avail Clinical Research, LLC
DeLand, Florida
Sarkis Clinical Trials
Lake City, Florida
Innovative Clinical Research Inc
Lauderhill, Florida
Suncoast Research Group
Miami, Florida
Renstar Medical Research
Ocala, Florida
Palm Beach Research Center
West Palm Beach, Florida
Atlanta Center for Medical Research
Atlanta, Georgia
NeuroTrials Research, Inc.
Atlanta, Georgia
Chicago Research Center
Chicago, Illinois
Centennial Medical Group
Elkridge, Maryland
Clinical Research Center of Nevada
Las Vegas, Nevada
Gastonia Medical Specialty Clinic
Gastonia, North Carolina
Clinical Research of Lake Norman
Mooresville, North Carolina
CTI Clinical Trial and Consulting Services
Cincinnati, Ohio
Lynn Health Science Institute
Oklahoma City, Oklahoma
Clinical Research of Charleston
Mt. Pleasant, South Carolina
FutureSearch Trials of Neurology, LP
Austin, Texas
Anima
Alken, Belgium
Cliniques Universitaires Saint Luc
Brussels, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
UZ Leuven Gasthuisberg
Leuven, Belgium
Universiteit Antwerpen
Wilrijk, Belgium
CHU de Grenoble Hopital Albert Michallon
Isere, France
Hopital de La Croix Rousse
Lyon, France
Hôpital Hôtel Dieu - Paris
Paris, France
Centre Hospitalier Specialisé de Rouffach
Rouffach, France
Advanced Sleep Research GmbH
Berlin, Germany
Emovis GmbH
Berlin, Germany
Synexus Clinical Research GmbH
Frankfurt, Germany
CTC North GmbH & Co. KG
Hamburg, Germany
Synexus Clinical Research GmbH
Sachsen, Germany
Somni Bene GmbH
Schwerin, Germany
Klinische Forschung Schwerin GmbH
Schwerin, Germany
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.